Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women (scientific article)

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

Q42943536

Factors that predict response of patients with hepatitis C virus infection to boceprevir

Q42980646

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

Q42986993

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

Q42989510

Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

Q43032172

Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response

Q43040495

Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results

Q45027152

Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin.

Q50569333

Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure.

Q54135674

Boceprevir for previously treated chronic HCV genotype 1 infection

Q24620576

Boceprevir for untreated chronic HCV genotype 1 infection

Q29620617

Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis

Q33404560

Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials

Q33414720

Reproductive status is associated with the severity of fibrosis in women with hepatitis C.

Q34412627

Changes in proinflammatory cytokine activity after menopause

Q34530773

Risk factors for liver fibrosis progression in patients with chronic hepatitis C.

Q35750053

Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy

Q35761351

Chronic hepatitis C and fibrosis: evidences for possible estrogen benefits

Q36904503

Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors

Q37159671

Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.

Q37879701

Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study

Q37883962

Genomics and HCV infection: progression of fibrosis and treatment response

Q38015672

Interleukin 28B genotype determination using DNA from different sources: A simple and reliable tool for the epidemiological and clinical characterization of hepatitis C.

Q38408305

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection

Q38462527

Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response

Q42247630

Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis

Q42259157

P433

issue

P407

language of work or name

English